Apr 11 |
Leap Therapeutics announces $40 million private placement
|
Apr 11 |
Leap Therapeutics Announces $40 Million Private Placement
|
Mar 20 |
Here's Why Leap Therapeutics (LPTX) is Poised for a Turnaround After Losing -28.92% in 4 Weeks
|
Mar 18 |
Leap Therapeutics files for $200M mixed shelf offering
|
Mar 18 |
Leap Therapeutics GAAP EPS of -$0.46 beats by $0.10
|
Mar 18 |
Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
|
Jan 16 |
Leap Therapeutics to Present New Clinical Data from Part A of DeFianCe Study at the 2024 ASCO Gastrointestinal Cancers Symposium
|
Jan 3 |
Leap Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference
|
Jan 2 |
Leap Therapeutics Announces Completion of Enrollment in Randomized Controlled Part C of the DisTinGuish Study of DKN-01 for the Treatment of Gastric Cancer Patients
|
Dec 11 |
Leap Therapeutics to Present New Data from Part A of the DeFianCe Study of DKN-01 Plus Bevacizumab and Chemotherapy in Colorectal Cancer Patients at the 2024 ASCO Gastrointestinal Cancers Symposium
|